JP2005532318A - 抗精神病薬としてのドーパミン受容体モジュレーター - Google Patents

抗精神病薬としてのドーパミン受容体モジュレーター Download PDF

Info

Publication number
JP2005532318A
JP2005532318A JP2004503446A JP2004503446A JP2005532318A JP 2005532318 A JP2005532318 A JP 2005532318A JP 2004503446 A JP2004503446 A JP 2004503446A JP 2004503446 A JP2004503446 A JP 2004503446A JP 2005532318 A JP2005532318 A JP 2005532318A
Authority
JP
Japan
Prior art keywords
alkyl
methyl
formula
compound
tetrahydro
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2004503446A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005532318A5 (cg-RX-API-DMAC7.html
Inventor
アンドリュー・デリック・グリブル
イアン・トムソン・フォーブズ
アンドリュー・ライトフット
アンドリュー・エイチ・ペイン
デイビッド・グウィン・クーパー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Group Ltd
Original Assignee
Glaxo Group Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Group Ltd filed Critical Glaxo Group Ltd
Publication of JP2005532318A publication Critical patent/JP2005532318A/ja
Publication of JP2005532318A5 publication Critical patent/JP2005532318A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
    • C07D223/16—Benzazepines; Hydrogenated benzazepines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/02—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines
    • C07D217/04—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with only hydrogen atoms or radicals containing only carbon and hydrogen atoms, directly attached to carbon atoms of the nitrogen-containing ring; Alkylene-bis-isoquinolines with hydrocarbon or substituted hydrocarbon radicals attached to the ring nitrogen atom

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Addiction (AREA)
  • Child & Adolescent Psychology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Pain & Pain Management (AREA)
  • Otolaryngology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
JP2004503446A 2002-05-10 2003-05-09 抗精神病薬としてのドーパミン受容体モジュレーター Pending JP2005532318A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0210762.1A GB0210762D0 (en) 2002-05-10 2002-05-10 Compounds
PCT/GB2003/001983 WO2003095428A1 (en) 2002-05-10 2003-05-09 Dopamine receptor modulators as antipsychotic agents

Publications (2)

Publication Number Publication Date
JP2005532318A true JP2005532318A (ja) 2005-10-27
JP2005532318A5 JP2005532318A5 (cg-RX-API-DMAC7.html) 2006-06-29

Family

ID=9936447

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2004503446A Pending JP2005532318A (ja) 2002-05-10 2003-05-09 抗精神病薬としてのドーパミン受容体モジュレーター

Country Status (6)

Country Link
US (1) US20070043026A1 (cg-RX-API-DMAC7.html)
EP (1) EP1503989A1 (cg-RX-API-DMAC7.html)
JP (1) JP2005532318A (cg-RX-API-DMAC7.html)
AU (1) AU2003227919A1 (cg-RX-API-DMAC7.html)
GB (1) GB0210762D0 (cg-RX-API-DMAC7.html)
WO (1) WO2003095428A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009531318A (ja) * 2006-03-23 2009-09-03 ラボラトリオス デル ドクトル エステヴェ ソシエダッド アノニマ 置換テトラヒドロイソキノリン化合物、その調製及び医薬における使用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY133587A (en) 2002-05-29 2007-11-30 Glaxo Group Ltd Aromatic sulfones and their medical use
GB0329214D0 (en) * 2003-12-17 2004-01-21 Glaxo Group Ltd Novel compounds
US20050137186A1 (en) * 2003-12-18 2005-06-23 Abbott Gmbh & Co. Kg. Tetrahydrobenzazepines and their use
US8207160B2 (en) 2003-12-18 2012-06-26 Abbott Gmbh & Co. Kg Tetrahydrobenzazepines and their use in he modulation of the dopamine D3 receptor
TW200611701A (en) * 2004-06-18 2006-04-16 Glaxo Group Ltd Novel compounds
EP2371814A1 (en) * 2004-10-14 2011-10-05 Abbott GmbH & Co. KG Aminoethylaromatic compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor
US7897595B2 (en) 2006-05-26 2011-03-01 Forest Laboratories Holdings Limited Pyridoazepine derivatives
US8258134B2 (en) * 2008-04-16 2012-09-04 Hoffmann-La Roche Inc. Pyridazinone glucokinase activators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4321254A (en) * 1980-09-26 1982-03-23 Smithkline Corporation Antiallergic imidodisulfamides
US5112824A (en) * 1989-12-08 1992-05-12 Merck & Co., Inc. Benzofuran compounds as class III antiarrhythmic agents
US5684195A (en) * 1994-07-14 1997-11-04 G. D. Searle & Co. Method of preparing sulfmonamides from sulfones
NZ332757A (en) * 1996-06-17 1999-06-29 Smithkline Beecham Plc Substituted tetrahydroisoquinoline benzamide derivatives and their use as anticonvulsants and psycho-active agents
IL131756A0 (en) * 1997-03-18 2001-03-19 Smithkline Beecham Plc Substituted isoquinoline derivatives and their use as anticonvulsants
JP2001521026A (ja) * 1997-10-24 2001-11-06 スミスクライン・ビーチャム・パブリック・リミテッド・カンパニー 置換イソキノリン誘導体および抗痙攣薬としての使用
DE10053799A1 (de) * 2000-10-30 2002-05-08 Bayer Ag Verwendung von Tetrahydroisochinolinsulfonamiden

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009531318A (ja) * 2006-03-23 2009-09-03 ラボラトリオス デル ドクトル エステヴェ ソシエダッド アノニマ 置換テトラヒドロイソキノリン化合物、その調製及び医薬における使用

Also Published As

Publication number Publication date
WO2003095428A1 (en) 2003-11-20
AU2003227919A1 (en) 2003-11-11
US20070043026A1 (en) 2007-02-22
EP1503989A1 (en) 2005-02-09
GB0210762D0 (en) 2002-06-19

Similar Documents

Publication Publication Date Title
JP2005518414A (ja) ドーパミン受容体のモジュレーターとしての7−スルホニル−3−ベンゾアゼピン誘導体およびcns障害の治療のためのその使用
JP4091648B2 (ja) 2−(1h−インドリルスルファニル)−ベンジルアミン誘導体
JP4268126B2 (ja) 芳香族スルホン類およびそれらの医薬用途
JP2005526724A (ja) 抗精神病剤としてのベンゼンスルホンアミド誘導体
JP2011512389A (ja) 新規3−アミノアルキル−1,3−ジヒドロ−2h−インドール−2−オン誘導体、この調製、およびこの治療上の使用
US20070043026A1 (en) Dopamine receptor modulators as antipsychotic agents
US7662862B2 (en) 5-HT7 receptor antagonists
US20050085461A1 (en) Benzenesulfonamide derivatives
CN101014573A (zh) 5-ht7受体拮抗剂
JP2008509961A (ja) 5−ht7受容体アンタゴニスト
EP1549639B1 (en) Sulphonamide derivatives as antipsychotic agents
CN101010301A (zh) 5-ht7受体拮抗剂
JP2007512285A (ja) 抗精神病薬としての7−[4−(4−クロロベンジルオキシ)ベンゼンスルホニル]−8−メトキシ−3−メチル−2,3,4,5−テトラヒドロ−1h−3−ベンゾアゼピニウムマレエートもしくはトシレート
JP2005531580A (ja) 抗精神病薬としての7−フェニルスルホニル−テトラヒドロ−3−ベンゾアゼピン誘導体
US7553965B2 (en) 5-HT7 receptor antagonists
ZA200409417B (en) Compounds.
CN101184735A (zh) 苯并氮杂䓬马来酸盐衍生物的晶型

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060509

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20060509

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20091117

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100511